<story>
<id>682622</id>
<state>1</state>
<story_issue>no</story_issue>
<select_magazine>0</select_magazine>
<select_supplement/>
<issue_date/>
<bylines>
</bylines>
<createddate>1464784241</createddate>
<publisheddate>0</publisheddate>
<modifieddate>1464784241</modifieddate>
<createdby>0</createdby>
<modifiedby>0</modifiedby>
<cities>
<city/>
</cities>
<categories><category>279852</category></categories><ordering>682622</ordering><primarycategory>279852</primarycategory><extralargeimage/>
<extra_large_alt/>
<extra_large_title/>
<largeimage/>
<large_alt/>
<large_title/>
<mediumimage/>
<mediumimage_alt/>
<mediumimage_title/>
<smallimage/>
<smallimage_alt/>
<smallimage_title/>
<extrasmallimage/>
<extra_small_alt/>
<extra_small_title/>
<bigimage/>
<kicker_image_caption/>
<mosimage>
<image/><caption/></mosimage>
<pros_cons><tech_pros_cons_main><title/><rating/><pron_cons_img/></tech_pros_cons_main><tech_pros><item/><item/><item/></tech_pros><tech_cons><item/><item/></tech_cons></pros_cons><tech-image-gallery><image/></tech-image-gallery><fulltext_conclaveformat><listicle_title/>
<quote_title/>
<quote_image/>
<factoids_title/>
<listicle_content><listicle/>
</listicle_content>
<quotes><quote/>
</quotes>
<factoids_content><factoids/>
</factoids_content>
</fulltext_conclaveformat>
<storykicker><![CDATA[]]></storykicker>
<storybody><![CDATA[<p>Mumbai, Jun 1 (PTI) Headwinds plaguing the countrys largest drug-maker Sun Pharmaceutical will continue for next two-three quarters owing to pricing pressures and regulatory issues dogging its Halol plant, says a report. </p><p>The companys Halol plant has been under the scanner of US Food and Drug Administration (USFDA) for alleged violations of good manufacturing practices. </p><p>According to American brokerage Jefferies, Suns fourth quarter results reflect that the key headwinds to recovery still persist, coupled with pricing pressure. </p><p>The Halol plant contributes 7-8 per cent of Suns sales and 15 per cent of its US sales. More than 50 per cent of Suns annual sales come from the US. </p><p>"Given the increased pricing pressure and significant investment, our base business recovery timelines are pushed out another 6-9 months," Jefferies said in a note today. </p><p>The brokerage also noted that the firms fourth quarter revenue growth of 8 per cent was below expectations. </p><p>Sun had earlier this week reported a consolidated net profit of Rs 1,713.69 crore for the March quarter, up from Rs 889.24 crore in the same period the previous year. </p><p>The consolidated total income of the group increased to Rs 7,599.21 crore as against Rs 6,505.04 crore a year ago. </p><p>As per Jefferies, Halol remediation is still ongoing and should be completed by June end. </p><p>"This indicates a 3-4 month delay versus our expectation in resolution. It expects to invite the FDA for re-inspection by end June and we expect resolution by the fourth quarter," the brokerage said. </p><p>The Sun counter closed 1 per cent down on the BSE at Rs 755.40, while the benchmark Sensex gained 46 points. The Sun stock is down 23 per cent from its 52-week high of Rs 979.25, while its m-cap stood at Rs 181,809.67 crore. PTI SSM BEN NSK ABM BAS</p>]]></storybody>
<magazinekicker><![CDATA[]]></magazinekicker><tags>
<tag>355868</tag>
<tag>494027</tag>
<tag>621819</tag>
<tag>734445</tag>
<tag>832415</tag>
<tag>280436</tag>
<tag>508087</tag>
<tag>277703</tag>
<tag>1126573</tag>
<tag>297217</tag>
</tags>
<shortheadline><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></shortheadline>
<storytitle><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></storytitle>
<short_introtext/>
<magazineheadline><![CDATA[]]></magazineheadline>
<longheadline><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></longheadline>
<strapheadline><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></strapheadline>
<storyrating/>
<like_dislike>
<like>0</like>
<dislike>0</dislike>
</like_dislike>
<newtitle/>
<redirectionurl><![CDATA[http://indiatoday.intoday.in/story/suns-problems-to-linger-on-for-2-3-quarters-jefferies/1/682622.html]]></redirectionurl>
<courtesy><![CDATA[null]]></courtesy>
<snappost>no</snappost>
<socialmediaintegration>
<facebook/>
<facebook_instant_article>0</facebook_instant_article>
<twitter/>
</socialmediaintegration>
<facebook_instant_article_integration>
<facebook_instant_article>0</facebook_instant_article>
<audio_position/>
<audio_url/>
<animated_image_position/>
<animated_image/>
<map_embed_code_position/>
<map_embed_code/>
<gallery_associate_content>
<gallery_associate>
<gallery_id_position/>
<gallery_id/>
</gallery_associate>
</gallery_associate_content>
<social_embed_code_position/>
<social_embed_code/>
</facebook_instant_article_integration>
<facebooknarrative><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></facebooknarrative>
<facebookimage/>
<facebookvideonarrative/>
<facebookvideo/>
<twitternarrative><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></twitternarrative>
<twitterimage/>
<twittervideodescription/>
<twittervideo/>
<syndication>0</syndication>
<syndications_photo>0</syndications_photo>
<noindex_nofollow>0</noindex_nofollow>
<content_type_tag/>
<configurations>
<breakingnews>0</breakingnews>
<googlestandout>0</googlestandout>
<comment>0</comment>
<mediumstylecomment>0</mediumstylecomment>
<displaylock>0</displaylock>
</configurations>
<commentbox>1</commentbox>
<commentquestion/>
<featuredname/>
<relatedcontents/>
<scheduledatetime/>
<storyexpires/>
<storyexpirydate/>
<selectlisticletemplates/>
<quotes>
<quote/>
</quotes>
<blurbs>
<blurb/>
</blurbs>
<tables>
<table><![CDATA[]]></table>
</tables>
<external_url/>
<buzz_content>
<buzz>
<headline/>
<image/>
<description/>
</buzz>
<buzz>
<headline/>
<image/>
<description/>
</buzz>
</buzz_content>
<briefcase_content><briefcase/></briefcase_content><expertname/>
<expertimage/>
<expertdescription/>
<archive/>
<associatetvdate/>
<metatags>
<sefurl><![CDATA[suns-problems-to-linger-on-for-2-3-quarters-jefferies]]></sefurl>
<pagetitle><![CDATA[Suns problems to linger on for 2-3 quarters: Jefferies]]></pagetitle>
<keywords><![CDATA[Halol plant,American brokerage Jefferies,Suns annual sales,largest drug-maker Sun,companys Halol plant,good manufacturing practices,quarter revenue growth,cent,pricing pressure,PTI SSM BEN]]></keywords>
</metatags>
</story>